TrianglePhase I Trial of BCMA-TGF-BETA CAR-T… (NCT05976555)
Phase I Trial of BCMA-TGF-BETA CAR-T Cell… trial for Multiple Myeloma (NCT05976555). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
Lo que dice el vídeo
Lee la transcripción
Multiple myeloma keeps coming back. CAR T cells against a marker called BCMA can clear it for a time, but most patients eventually relapse.
The idea: armor the cells against the signal the tumor uses to switch them off.
Myeloma bone marrow is rich in TGF-beta, a molecule that quiets immune cells. Here, a patient's T cells receive the BCMA receptor plus a change that makes them insensitive to TGF-beta, so they keep working where ordinary CAR T cells are dampened. The cells are grown with interleukin-7 and -15, favoring younger, longer-lived cells.
An early dose-finding trial in adults after three or more prior therapies, including prior BCMA drugs.
Binod Dhakal leads it at the Medical College of Wisconsin. Public record; not medical advice.
¿Ya estás en un ensayo?
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.